<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35584696</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-0024</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Molecular therapy : the journal of the American Society of Gene Therapy</Title><ISOAbbreviation>Mol Ther</ISOAbbreviation></Journal><ArticleTitle>Stereopure oligo therapy for ALS.</ArticleTitle><Pagination><StartPage>2116</StartPage><EndPage>2117</EndPage><MedlinePgn>2116-2117</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ymthe.2022.04.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1525-0016(22)00297-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>City of Hope, Duarte, CA, USA. Electronic address: jrossi@coh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AI161075</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther</MedlineTA><NlmUniqueID>100890581</NlmUniqueID><ISSNLinking>1525-0016</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35584696</ArticleId><ArticleId IdType="pmc">PMC9171261</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2022.04.026</ArticleId><ArticleId IdType="pii">S1525-0016(22)00297-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu Y., Andreucci A., Iwamoto N., Yin Y., Yang H., Liu F., Bulychev A., Hu X.S., Lin X., Lamore S., et al. Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD. Mol. Ther. Nucleic Acids. 2022 doi: 10.1016/j.omtn.2022.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2022.04.007</ArticleId><ArticleId IdType="pmc">PMC9092894</ArticleId><ArticleId IdType="pubmed">35592494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U S A. 1978;75:280&#x2013;284. doi: 10.1073/pnas.75.1.280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.75.1.280</ArticleId><ArticleId IdType="pmc">PMC411230</ArticleId><ArticleId IdType="pubmed">75545</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke S. Progress in antisense technology. Ann. Rev. Med. 2004;55:61&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">14746510</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in Noncoding Region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>